Skip to main content

Table 2 Characteristics on 21 patients (18 %) with loco-regional failure (LRF) are listed; patients with isolated distant failure (DF) are not included in this list. Mean time to failure (TTF) was 5 – 6 months in recurred patients; in 8 individuals (1/3) tumor persistence was observed.

From: IMRT using simultaneously integrated boost (SIB) in head and neck cancer patients

Number Diagnosis TNM LRF DF Outcome TTF (m) GTV PT (cc) GTV LN (cc) PTV1 (cc) %PTV <95 %PTV < 93%
1 OC T4N2c LRR   AD 4 15 3 127 9 5
2 OC T4N2c LRR   DOD 10 75 27 253 6 3
3 OC T1N2b LR distant DOD 3 na 6.5 74 5 2
4 OC T3N2c LR   DOD 15 23 1 144 14 9
5 OC T2N1 LR   AD 4 45 2 124 5 2
6 OC Recurrence LRR   AD 0 71 6 117 25 17
7 OC T2N0 Persistence   AD 0 13 0 64 0 0
8 OC T2N2c Persistence   AD 0 16 2.4 82 50 7
9 OC T4N1 Persistence   DOD 0 206 5 270 4 1
10 oro T4N2b LR distant AD 13 100 2 255 8 4
11 oro T4N2c NR distant DOD 3 34 15 179 8 4
12 oro T4N0 Persistence   DOD 0 57 0 188 5 2
13 oro T3N2b Persistence distant AD 0 97 5 393 14 5
14 oro T3N2a Persistence   AD 0 31 4.3 198 35 25
15 oro T4N2b LRR   AD 8 41 5 178 15 10
16 Sinus T4N0 Persistence   DOD 10 75 0 75 8 5
17 Sinus Recurrence Persistence distant AD 0 56 20 89 27 11
18 Sinus T4N2b LRR   DOD 15 141 17 176 11 5
19 Glottic Recurrence NR distant DOD 13 9 118 8 3 3
20 Supragl T4N2c LRR distant AD 6 79 18 353 7 2
21 Hypoph T3N2c NR   ANED * 9 22 30 210 15 7
Mean       5.4 63.0 8.5 174.6 13.3 6.1
Range       0 – 21 9 – 206 0 – 99 64 – 353 0 – 50 0 – 25
  1. LRF loco-regional failure; DF distant failure; LC local recurrence; LRR loco-regional recurrence; NR nodal recurrence; TTF time to failure; GTVPT primary gross tumor volume, GTV LN lymph node gross tumor volume; PTV1 planning target volume 1 (boost).